Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: A randomized open blinded end-point (PROBE) trial

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 12, 2011, Pages 1359-1368

  Caglar N ^a   Dincer, I ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Hypertension; Left ventricular hypertrophy; Left ventricular mass index; Nebivolol; Ramipril

Indexed keywords

HYDROCHLOROTHIAZIDE; INDAPAMIDE; NEBIVOLOL; RAMIPRIL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY SURFACE; CALCULATION; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LEFT VENTRICULAR MASS INDEX; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPHYGMOMANOMETER; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; WEIGHT, MASS AND SIZE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; ECHOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 84857014683     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. BOMBELLI M, FACCHETTI R, CARUGO S, MADOTTO F, ARENARE F, Q UARTI-TREVANO F, C APRA A, GIANNATTASIO C, DELL'ORO R, GRASSI G, SEGA R, MANCIA G. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009; 27: 2458-2464.
2. MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, LAURENT S, NARKIEWICZ K, RUILOPE L, RYNKIEWICZ A, SCHMIEDER RE, STRUIJKER BOUDIER HA, ZANCHETTI A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, D ICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, Z AMORA-NO JL, KJELDSEN SE, ERDINE S, NARKIEWICZ K, KIOWSKI W, A GABITI-ROSEI E, AMBROSIONI E, CIFKOVA R, DO-MINICZAK A, FAGARD R, HEAGERTY AM, LAURENT S, LINDHOLM LH, MANCIA G, MANOLIS A, NILSSON PM, REDON J, SCHMIEDER RE, STRUIJKER-BOUDIER HA, VIIGIMAA M, FILIPPATOS G, ADAMOPOULOS S, AGABITI-ROSEI E, AM-BROSIONI E, BERTOMEU V, C LEMENT D, ERDINE S, FARSANG C, GAITA D, KIOWSKI W, L IP G, MALLION JM, MANOLIS AJ, NILSSON PM, O'BRIEN E, PONIKOWSKI P, REDON J, RUSCHITZKA F, T AMARGO J, VAN ZWIETEN P, V I-IGIMAA M, WAEBER B, WILLIAMS B, ZAMORANO JL. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
3. OKIN PM, DEVEREUX RB, JERN S, KJELDSEN SE, JULIUS S, NIEMINEN MS, SNAPINN S, HARRIS KE, AURUP P, E DEL-MAN JM, WEDEL H, LINDHOLM LH, DAHLÖF B; LIFE STUDY INVESTIGATORS. Regression of electrocardio-graphic left ventricular hypertrophy during antihy-pertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-2349. (Pubitemid 39491918)
4. DE SIMONE G, GOTTDIENER JS, CHINALI M, MAURER MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008; 29: 741-747. (Pubitemid 351431013)
5. OKIN PM, GERDTS E, WACHTELL K, OIKARINEN L, NIEMINEN MS, DAHLÖF B, DEVEREUX RB. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens 2010; 28: 1534-1540.
6. SCHMIEDER RE, KJELDSEN SE, JULIUS S, MCINNES G, ZANCHETTI A, HUA T. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE-trial. J Hypertens 2006; 24(Suppl): S3.
7. DEVEREUX RB, DAHLÖF B, GERDTS E, BOMAN K, NIEMINEN MS, PAPADEMETRIOU V, R OKKEDAL J, HARRIS KE, EDELMAN JM, WACHTELL K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-1462. (Pubitemid 39238023)
8. FAGARD RH, CELIS H, THIJS L, WOUTERS S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-1091.
9. OKIN PM, DEVEREUX RB, HARRIS KE, JERN S, KJELDSEN SE, JULIUS S, EDELMAN JM, DAHLÖF B; LIFE STUDY INVESTIGATORS. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007; 147: 311-319. (Pubitemid 351664558)
10. SCHMIEDER RE. The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 2005; 20: 2610-2612. (Pubitemid 41672256)
11. ZHONG J, BASU R, GUO D, CHOW FL, BYRNS S, SCHUSTER M, LOIBNER H, WANG XH, PENNINGER JM, KASSIRI Z, OUDIT GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122: 717-728, 718 p following 728.
12. COWAN BR, YOUNG AA, ANDERSON C, DOUGHTY RN, KRITTAYAPHONG R, LONN E, MARWICK TH, REID CM, SANDERSON JE, SCHMIEDER RE, TEO K, WADHAM AK, WORTHLEY SG, YU CM, YUSUF S, JENNINGS GL; ON-TARGET INVESTIGATORS. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmis-artan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardi-ol 2009; 104: 1484-1489.
13. DE LUCA N, MALLION JM, O'ROURKE M F, O'BRIEN E, RAHN KH, TRIMARCO B, ROMERO R, DE LEEUW PW, HITZENBERGER G, BATTEGAY E, DUPREZ D, SEVER P, S AFAR ME. Regression of left ventricular mass in hypertensive patients treated with perindo-pril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hyper-tens 2004; 17: 660-667. (Pubitemid 39091546)
14. TSUTAMOTO T, N ISHIYAMA K, YAMAJI M, KAWAHARA C, FUJII M, YAMAMOTO T, H ORIE M. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 2010; 33: 118-122.
15. VERDECCHIA P, S LEIGHT P, M ANCIA G, FAGARD R, TRIMARCO B, SCHMIEDER RE, KIM JH, JENNINGS G, JANSKY P, C HEN JH, LIU L, GAO P, P ROBSTFIELD J, TEO K, YUSUF S, ON-TARGET/TRANSCEND INVESTIGATORS. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120:1380-1389.
16. MOEN MD, WAGSTAFF AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006; 66: 1389-1409; discussion 1410.
17. ANDRE DE, ARNET U, YANG Z, LUSCHER TF. Nebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteins. J Cardio-vasc Pharmacol 2000; 35: 845-848. (Pubitemid 30327511)
18. IGNARRO LJ, SISODIA M, TRINH K, BEDROOD S, WU G, WEI LH, BUGA GM. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002; 7: 83-90. (Pubitemid 35176999)
19. PIRES MJ, RODRÍGUEZ-PEÑA AB, ARÉVALO M, CENADOR B, EVANGELISTA S, ESTELLER A, SÁNCHEZ-RODRÍGUEZ A, COLAÇO A, LÓPEZ-NOVOA JM. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007; 25: 2486-2496. (Pubitemid 350060388)
20. TOBLLI J, CAO G, RIVAS C, MUNOZ M, GIANI J, DOMINI-CI F, A NGEROSA M. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hyper-tens 2010; 28: 1007-1019.
21. WOLF SC, SAUTER G, PREYER M, POERNER T, K EMPF VA, RISLER T, B REHM BR. Influence of nebivolol and meto-prolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007; 19: 129-136.
22. VAN BORTEL LM, FICI F, M ASCAGNI F. Efficacy and tol-erability of nebivolol compared with other antihy-pertensive drugs: a meta-analysis. Am J Cardio-vasc Drugs 2008; 8: 35-44. (Pubitemid 351311518)
23. FOUNTOULAKI K, DIMOPOULOS V, G IANNAKOULIS J, ZINTZARAS E, TRIPOSKIADIS F. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am J Hy-pertens 2005; 18: 171-177. (Pubitemid 40332545)
24. SAHN DJ, DEMARIA A, KISSLO J, WEYMAN A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocar-diographic measurements. Circulation 1978; 58: 1072-1083. (Pubitemid 9091990)
25. DEVEREUX RB, ALONSO DR, LUTAS EM, GOTTLIEB GJ, CAMPO E, SACHS I, REICHEK N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458. (Pubitemid 16119719)
26. CUSPIDI C, GIUDICI V, N EGRI F, M EANI S, SALA C, ZANCHETTI A, MANCIA G. Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height. J Hypertens 2009; 27: 2465-247.
27. DE SIMONE G, DEVEREUX RB, DANIELS SR, KOREN MJ, MEYER RA, LARAGH JH. Effect of growth on variability of left ventricular mass: assessment of allomet-ric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062.
28. LANG RM, BIERIG M, DEVEREUX RB, FLACHSKAMPF FA, FOSTER E, PELLIKKA PA, PICARD MH, ROMAN MJ, SE-WARD J, SHANEWISE J, SOLOMON S, SPENCER KT, ST JOHN SUTTON M, STEWART W; AMERICAN SOCIETY OF ECHOCARDIOGRAPHY'S NOMENCLATURE AND STANDARDS COMMITTEE; TASK FORCE ON CHAMBER QUANTIFICATION; AMERICAN COLLEGE OF CARDIOLOGY ECHOCARDIOGRAPHY COMMITTEE; AMERICAN HEART ASSOCIATION; EUROPEAN ASSOCIATION OF ECHOCARDIOGRAPHY, EUROPEAN SOCIETY OF CARDIOLOGY. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108. (Pubitemid 43257193)
29. CUSPIDI C, GIUDICI V, L ONATI L, SALA C, VALERIO C, MANCIA G. Left ventricular hypertrophy detection and body mass index in essential hypertension. Blood Press 2010; 19: 337-343.
30. MATHEW J, SLEIGHT P, L ONN E, JOHNSTONE D, POGUE J, YI Q, BOSCH J, SUSSEX B, PROBSTFIELD J, YUSUF S; HEART OUTCOMES PREVENTION EVALUATION (HOPE) INVESTIGATORS. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-con-verting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-1621. (Pubitemid 32947523)
31. LONN E, SHAIKHOLESLAMI R, YI Q, BOSCH J, SULLIVAN B, TANSER P, M AGI A, YUSUF S. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a sub-study of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004; 43: 2200-2206. (Pubitemid 38757585)
32. CUSPIDI C, MUIESAN ML, VALAGUSSA L, SALVETTI M, DI BIAGIO C, AGABITI-ROSEI E, MAGNANI B, ZANCHETTI A; CATCH INVESTIGATORS. Comparative effects of can-desartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300. (Pubitemid 35388249)
33. GALZERANO D, TAMMARO P, DEL VISCOVO L, LAMA D, GALZERANO A, BREGLIO R, TUCCILLO B, PAOLISSO G, CA-POGROSSO P. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005; 18: 1563-1569. (Pubitemid 41818964)
34. GRANDI AM, SOLBIATI F, L AURITA E, MARESCA AM, NICOLINI E, MARCHESI C, GIANNI M, GUASTI L, VENCO A. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008; 21: 231-237. (Pubitemid 351231577)
35. DAHLOF B, ZANCHETTI A, DIEZ J, NICHOLLS MG, YU CM, BARRIOS V, A URUP P, S MITH RD, JOHANSSON M; REGAAL STUDY INVESTIGATORS. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hyper-tens 2002; 20: 1855-1864.
36. OKIN PM, DEVEREUX RB, JERN S, KJELDSEN SE, JULIUS S, NIEMINEN MS, SNAPINN S, HARRIS KE, AURUP P, E DEL-MAN JM, DAHLOF B. Regression of electrocardio-graphic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690. (Pubitemid 36999252)
37. CUSPIDI C, GIUDICI V, N EGRI F, S ALA C, MANCIA G. Left ventricular geometry, ambulatory blood pressure and extra-cardiac organ damage in untreated essential hypertension. Blood Press Monit 2010; 15: 124-131.
38. GALDERISI M, D'ERRICO A, SIDIROPULOS M, INNELLI P, DE DIVITIIS O, DE SIMONE G. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. J Hypertens 2009; 27: 2108-2115.
39. MAFFEI A, DI PARDO A, CARANGI R, CARULLO P, P OULET R, GENTILE MT, VECCHIONE C, LEMBO G. NEBIVOLOL induces nitric oxide release in the heart through in-ducible nitric oxide synthase activation. Hypertension 2007; 50: 652-656. (Pubitemid 47442727)
40. BREHM BR, WOLF SC, BERTSCH D, KLAUSSNER M, WESSELBORG S, SCHÜLER S, SCHULZE-OSTHOFF K. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49: 430-439. (Pubitemid 32119560)
41. CIULLA M, PALIOTTI R, HESS DB, TJAHJA E, CAMPBELL SE, MAGRINI F, W EBER KT. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-664. (Pubitemid 127799951)
42. CUSPIDI C, CIULLA M, ZANCHETTI A. Hypertensive my-ocardial fibrosis. Nephrol Dial Transplant 2006; 21: 20-23.
43. DHAKAM Z, YASMIN, MCENIERY CM, BURTON T, B ROWN MJ, WILKINSON IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hy-pertens 2008; 26: 351-356.
44. MCENIERY CM, SCHMITT M, QASEM A, WEBB DJ, AVO-LIO A P, WILKINSON IB, COCKCROFT JR. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305-310. (Pubitemid 39167227)
45. LAURENT S, COCKCROFT J, VAN BORTEL L, BOUTOUYRIE P, G IANNATTASIO C, HAYOZ D, PANNIER B, VLACHOPOULOS C, WILKINSON I, STRUIJKER-BOUDI-ER H; EUROPEAN NETWORK FOR NON-INVASIVE INVESTIGATION OF LARGE ARTERIES. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605. (Pubitemid 44627304)
46. ROMAN MJ, OKIN PM, KIZER JR, LEE ET, HOWARD B V, DEVEREUX RB. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens 2010; 28: 384-388.
47. PIERDOMENICO SD, CUCCURULLO F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 2010; 23: 876-881.